Evidence map›Paper›PMID 30571410›Full record

ArticleStroke2018

Endocrine Regulator rFGF21 (Recombinant Human Fibroblast Growth Factor 21) Improves Neurological Outcomes Following Focal Ischemic Stroke of Type 2 Diabetes Mellitus Male Mice.

Yinghua Jiang, Ning Liu, Qingzhi Wang, Zhanyang Yu, Li Lin, Jing Yuan, Shuzhen Guo, Bum Ju Ahn, Xiao-Jie Wang, Xiaokun Li and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stroke, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Batokine in Central Nervous System Diseases.Molecular neurobiology · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Regulation of microglia polarization after cerebral ischemia.Frontiers in cellular neuroscience · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Yinghua JiangFrom the Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, China (Y.J., X.S., ).
Ning LiuNeuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (Y.J., N.L., Q.W., Z.Y., L.L., J.Y., S.G., B.J.A., E.H.L., X.W.).
Qingzhi WangNeuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (Y.J., N.L., Q.W., Z.Y., L.L., J.Y., S.G., B.J.A., E.H.L., X.W.).
Zhanyang YuNeuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (Y.J., N.L., Q.W., Z.Y., L.L., J.Y., S.G., B.J.A., E.H.L., X.W.).
Li LinNeuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (Y.J., N.L., Q.W., Z.Y., L.L., J.Y., S.G., B.J.A., E.H.L., X.W.).
Jing YuanNeuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (Y.J., N.L., Q.W., Z.Y., L.L., J.Y., S.G., B.J.A., E.H.L., X.W.).
Shuzhen GuoNeuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (Y.J., N.L., Q.W., Z.Y., L.L., J.Y., S.G., B.J.A., E.H.L., X.W.).
Bum Ju AhnNeuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (Y.J., N.L., Q.W., Z.Y., L.L., J.Y., S.G., B.J.A., E.H.L., X.W.).
Xiao-Jie WangKey Laboratory of Biotechnology and Pharmaceutical Engineering, School of Pharmaceutical Sciences, Wenzhou Medical University, Zhejiang, China (L.L., X.-J.W., X.L.).
Xiaokun LiKey Laboratory of Biotechnology and Pharmaceutical Engineering, School of Pharmaceutical Sciences, Wenzhou Medical University, Zhejiang, China (L.L., X.-J.W., X.L.).
Eng H LoNeuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (Y.J., N.L., Q.W., Z.Y., L.L., J.Y., S.G., B.J.A., E.H.L., X.W.).
Xiaochuan SunFrom the Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, China (Y.J., X.S., ).
Xiaoying WangNeuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (Y.J., N.L., Q.W., Z.Y., L.L., J.Y., S.G., B.J.A., E.H.L., X.W.).
Harvard University · USMassachusetts General Hospital · USFirst Affiliated Hospital of Zhengzhou University · CN

Funding

Recombinant FGF21 as a novel approach for treating ischemic stroke in type 2 diabetesR01NS099539 · NINDS · TULANE UNIVERSITY OF LOUISIANA · PI WANG, XIAOYING · 2016 to 2020
$1.8M
NINDS NIH HHS R01 NS099539
6 · The paper itself

Abstract

Background and Purpose- The complexity and heterogeneity of stroke, as well as the associated comorbidities, may render neuroprotective drugs less efficacious in clinical practice. Therefore, the development of targeted therapies to specific patient subsets has become a high priority in translational stroke research. Ischemic stroke with type 2 diabetes mellitus has a nearly double mortality rate and worse neurological outcomes. In the present study, we tested our hypothesis that rFGF21 (recombinant human fibroblast growth factor 21) administration is beneficial for improving neurological outcomes of ischemic stroke with type 2 diabetes mellitus. Methods- Type 2 diabetes mellitus db/db and nondiabetic genetic control db/+ mice were subjected into permanent focal ischemia of distal middle cerebral artery occlusion, we examined the effects of poststroke administration with rFGF21 in systemic metabolic disorders, inflammatory gatekeeper PPARγ (peroxisome proliferator-activated receptor γ) activity at 3 days, mRNA expression of inflammatory cytokines and microglia/macrophage activation at 7 days in the perilesion cortex, and last neurological function deficits, ischemic brain infarction, and white matter integrity up to 14 days after stroke of db/db mice. Results- After permanent focal ischemia, diabetic db/db mice presented confounding pathological features, including metabolic dysregulation, more severe brain damage, and neurological impairment, especially aggravated proinflammatory response and white matter integrity loss. However, daily rFGF21 treatment initiated at 6 hours after stroke for 14 days significantly normalized systemic metabolic disorders, rescued PPARγ activity decline, inhibited proinflammatory cytokine mRNA expression, and M1-like microglia/macrophage activation in the brain. Importantly, rFGF21 also significantly reduced white matter integrity loss, ischemic brain infarction, and neurological function deficits up to 14 days after stroke. The potential mechanisms of rFGF21 may in part consist of potent systematic metabolic regulation and PPARγ-activation promotion-associated antiproinflammatory roles in the brain. Conclusions- Taken together, these results suggest rFGF21 might be a novel and potent candidate of the disease-modifying strategy for treating ischemic stroke with type 2 diabetes mellitus.

Indexed as

Brain IschemiaDiabetes Mellitus, Type 2StrokeAnimalsBrainCytokinesDisease Models, AnimalFibroblast Growth FactorsInfarction, Middle Cerebral ArteryMacrophagesMaleMiceMicrogliaPPAR gammaRecombinant ProteinsRNA, MessengerCytokinesFGF22 protein, humanFibroblast Growth FactorsPPAR gammaRecombinant ProteinsRNA, Messengerdiabetes mellitusinflammationmicestrokewhite matter

Identifiers

PMID30571410
PMCPMC6310061
OpenAlexW2900297093

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.